EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Taiwan GEST ‐ TASL ‐ TMASO Joint Position Statement in Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity

Pin-Nan Cheng iD, Chia-Wen Lu iD, Chih-Lin Lin, Chien-Hsieh Chiang iD, Hwai-I Yang, Hsiang-Han Kao, Chia-Chi Wang iD, Tzu-Jung Chou, Ming-Lin Chang iD, Tun-Jen Hsiao, Cheng-Yuan Peng iD, Jee-Fu Huang iD und 7 weitere

Liver International · 2026-11 · 46 (11)

DOI: 10.1111/liv.70926 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 22.10.2026. Verfasst von Pin-Nan Cheng und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. Hauptthemen laut MEDLINE: Obesity, Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit nennt 89 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatotic liver disease (MASLD) and obesity share common pathogenesis and are increasingly relevant in clinical care. This joint statement addresses the need for comprehensive guidance in Taiwan for MASLD patients with obesity. The Gastroenterological Society of Taiwan, the Taiwan Association for the Study of the Liver, and the Taiwan Medical Association for the Study of Obesity conducted an evidence‐based review, integrating epidemiological data, clinical trial outcomes, and expert consensus to develop position statements covering diagnosis, disease burden, pathogenesis, surveillance, and therapeutic strategies. MASLD prevalence in Taiwanese adults is 30%–45%, reaching 60%–70% in individuals with obesity, with similar high prevalence in children and adolescents. Obesity accelerates hepatic and extrahepatic disease progression, including cirrhosis, hepatocellular carcinoma, and cardiovascular complications. Lifestyle interventions, glucagon‐like peptide‐1 receptor agonists, resmetirom, and bariatric surgery demonstrate efficacy in improving hepatic and metabolic outcomes. Risk stratification using noninvasive tools such as Fibrosis‐4 and vibration‐controlled transient elastography effectively guides referral and management. A multidisciplinary, precision‐based approach, integrating lifestyle modification, pharmacotherapy, surgical options, and risk stratification, is essential for effective MASLD management in patients with obesity, while research into artificial intelligence‐driven biomarkers, gut microbiota modulation, and genetic factors represents future directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityNon-alcoholic Fatty Liver DiseaseFatty LiverHumansTaiwanBariatric SurgerySocieties, MedicalPrevalence

Stichwörter der Autor:innen

GLP‐1 receptor agonistsbariatric surgerycardiometabolic riskfibrosisgut microbiotahepatic steatosislean MASLDliver diseasenonalcoholic steatohepatitisprecision medicine

Autor:innen und Institutionen

  • Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
  • College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Family Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Gastroenterology, Taipei City Hospital, Renai Branch, Taipei, Taiwan.
  • Department of Family Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.

ORCID-Profile: Pin-Nan Cheng, Chia-Wen Lu, Chien-Hsieh Chiang, Chia-Chi Wang, Ming-Lin Chang, Cheng-Yuan Peng, Jee-Fu Huang, Tsung-Po Chen, Chia-Yen Dai, Ming-Lung Yu, Kuo-Chin Huang, Jia-Horng Kao, Chun-Jen Liu

Zitieren

APA

Cheng, P. N., Lu, C. W., Lin, C. L., Chiang, C. H., Yang, H. I., Kao, H. H., Wang, C. C., Chou, T. J., Chang, M. L., Hsiao, T. J., Peng, C. Y., Huang, J. F., Chen, T. P., Dai, C. Y., Yu, M. L., Huang, K. C., Kao, J. H., Lin, W. Y., & Liu, C. J. (2026). Taiwan GEST ‐ TASL ‐ TMASO Joint Position Statement in Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity. Liver International, 46(11). https://doi.org/10.1111/liv.70926

Vancouver

Cheng PN, Lu CW, Lin CL, Chiang CH, Yang HI, Kao HH, et al. Taiwan GEST ‐ TASL ‐ TMASO Joint Position Statement in Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity. Liver International. 2026;46(11). doi:10.1111/liv.70926

BibTeX
@article{Cheng2026,
  author = {Cheng, Pin-Nan and Lu, Chia-Wen and Lin, Chih-Lin and Chiang, Chien-Hsieh and Yang, Hwai-I and Kao, Hsiang-Han and Wang, Chia-Chi and Chou, Tzu-Jung and Chang, Ming-Lin and Hsiao, Tun-Jen and Peng, Cheng-Yuan and Huang, Jee-Fu and Chen, Tsung-Po and Dai, Chia-Yen and Yu, Ming-Lung and Huang, Kuo-Chin and Kao, Jia-Horng and Lin, Wen-Yuan and Liu, Chun-Jen},
  title = {Taiwan GEST ‐ TASL ‐ TMASO Joint Position Statement in Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {11},
  doi = {10.1111/liv.70926}
}
Kostenlos starten →